6-chloro-2-fluoro-N-imidazo[1,2-a]pyridin-3-yl-3-(propane-1-sulfonylamino)benzamide | 1103232-88-7

• 分子结构分类: 有机化合物 - 有机杂环化合物
• 英文名称: 6-chloro-2-fluoro-N-imidazo[1,2-a]pyridin-3-yl-3-(propane-1-sulfonylamino)benzamide
• 英文别名: 6-chloro-2-fluoro-N-imidazo[1,2-a]pyridin-3-yl-3-(propylsulfonylamino)benzamide
• CAS: 1103232-88-7
• 化学式: C₁₇H₁₆ClFN₄O₃S
• 分子量: 410.856
• InChiKey: XQVSRTFBHRXEFG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  27
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  101
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• [EN] COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR<br/>[FR] COMPOSÉS ET PROCÉDÉS POUR LA MODULATION DES KINASES ET LEURS INDICATIONS
  申请人：PLEXXIKON INC

  公开号：WO2009012283A1

  公开（公告）日：2009-01-22

  Compounds of formula I active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases. Formula (I) wherein Ar is optionally substituted heteroaryl; R2 is hydrogen, lower alkyl or halogen; U is selected from the group consisting of -S(O)2-, -C(X)-, -C(X)-N(R10)-, and -S(O)2-N(R10)-; R3 is optionally substituted lower alkyl, optionally substituted C3.6 cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl or optionally substituted heteroaryl; and wherein R1, R3, R4, m, L1, X R10 are as described herein.

  化合物的结构式I描述了对蛋白激酶具有活性的化合物，以及使用这些化合物治疗与蛋白激酶异常活性相关的疾病和症状的方法。其中Ar是可选择取代的杂芳基；R2是氢、低碳基或卤素；U选自由-S(O)2-、-C(X)-、-C(X)-N(R10)-和-S(O)2-N(R10)-组成的群；R3是可选择取代的低碳基、可选择取代的C3.6环烷基、可选择取代的杂环烷基、可选择取代的芳基或可选择取代的杂芳基；其中R1、R3、R4、m、L1、X和R10如本文所述。
• [EN] SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS<br/>[FR] FORMES SOLIDES DE SULFONAMIDES ET D'ACIDES AMINÉS
  申请人：PLEXXIKON INC

  公开号：WO2010129570A1

  公开（公告）日：2010-11-11

  Solid forms of phenyl sulfonamide compounds of formula (I) active on protein kinases, including Raf protein kinases, are described, as well as methods of using such solid forms to treat diseases and conditions associated with activity of protein kinases, e.g. Raf protein kinases, including pain, polycystic kidney disease, melanoma and colorectal cancer.

  本文描述了公式（I）的苯基磺酰胺化合物的固体形式，其在蛋白激酶中具有活性，包括Raf蛋白激酶，以及使用这些固体形式治疗与蛋白激酶活性相关的疾病和病况的方法，例如疼痛、多囊肾病、黑色素瘤和结直肠癌。
• COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR
  申请人：Wu Guoxian

  公开号：US20100190777A1

  公开（公告）日：2010-07-29

  Compounds of formula I active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases. Formula (I) wherein Ar is optionally substituted heteroaryl; R 2 is hydrogen, lower alkyl or halogen; U is selected from the group consisting of —S(O) 2 —, —C(X)—, —C(X)—N(R 10 )—, and —S(O) 2 —N(R 10 )—; R 3 is optionally substituted lower alkyl, optionally substituted C3.6 cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl or optionally substituted heteroaryl; and wherein R 1 , R 3 , R 4 , m, L 1 , X R 10 are as described herein.

  本文描述了公式I的化合物对蛋白激酶的活性，以及使用这些化合物治疗与蛋白激酶异常活性相关的疾病和病况的方法。公式（I）中，Ar是可选的取代杂环芳基；R2是氢、低碳基或卤素；U选自由基组，包括—S（O）2—、—C（X）—、—C（X）—N（R10）—和—S（O）2—N（R10）—；R3是可选的取代低碳基、可选的取代C3.6环烷基、可选的取代杂环烷基、可选的取代芳基或可选的取代杂环芳基；其中R1、R3、R4、m、L1、X和R10如本文所述。
• SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS
  申请人：Visor Gary Conard

  公开号：US20120122860A1

  公开（公告）日：2012-05-17

  Solid forms of phenyl sulfonamide compounds of formula (I) active on protein kinases, including Raf protein kinases, are described, as well as methods of using such solid forms to treat diseases and conditions associated with activity of protein kinases, e.g. Raf protein kinases, including pain, polycystic kidney disease, melanoma and colorectal cancer.

  本文描述了公式（I）的苯基磺酰胺化合物的固态形式，这些化合物对蛋白激酶具有活性，包括Raf蛋白激酶，并描述了使用这些固态形式治疗与蛋白激酶活性相关的疾病和病况的方法，例如疼痛，多囊肾病，黑色素瘤和结肠直肠癌。
• Compounds and methods for kinase modulation, and indications therefor
  申请人：Plexxikon Inc.

  公开号：US10426760B2

  公开（公告）日：2019-10-01

  Compounds active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.

  本文介绍了对蛋白激酶有活性的化合物，以及使用这些化合物治疗与蛋白激酶活性异常有关的疾病和病症的方法。